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Abstract
Background: Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHSR), has two
major functions: the stimulation of the growth hormone production and the stimulation of food intake.
Accumulating evidence also indicates a role of ghrelin in cancer development.
Methods: We conducted a case-control study to examine the association of common genetic variants in the
genes coding for ghrelin (GHRL) and its receptor (GHSR) with colorectal cancer risk. Pairwise tagging was used to
select the 11 polymorphisms included in the study. The selected polymorphisms were genotyped in 680 cases and
593 controls from the Czech Republic.
Results: We found two SNPs associated with lower risk of colorectal cancer, namely SNPs rs27647 and rs35683. We
replicated the two hits, in additional 569 cases and 726 controls from Germany.
Conclusion: A joint analysis of the two populations indicated that the T allele of rs27647 SNP exerted a protective
borderline effect (Ptrend = 0.004).
Background
Ghrelin, an endogenous ligand for the growth hormone
secretagogue receptor (GHSR), is a 28-amino residue
peptide predominantly produced by the stomach [1]. In
addition to the mature form of ghrelin, several post-
transcriptional and post-translational variants have been
reported [2]. Two molecular forms (ghrelin and des-acyl
ghrelin) resulting from a different post-transcriptional
modification of the protein, are observed in human
plasma. The ghrelin receptor has two known isoforms:
one which is functional (GHSR-1a) and one spliced var-
iant (GHSR-1b) with no known function [3]. Only the
acylated form of ghrelin can bind the GHSR-1a receptor
[1]. Two main functions of ghrelin are documented: first
to stimulate growth hormone (GH) production through
the activation of the GHSR-1a in the hypothalamus [4]
and second to increase appetite and food intake [5,6] by
mechanisms that could be independent of GHSR [7].
Circulating ghrelin levels are correlated with obesity,
and insulin may be an important regulator of plasma
ghrelin levels in different states of nutrition [8-11]. Sev-
eral studies of different populations have shown that
levels of ghrelin are related to body size [12], although
its mode of action as a regulator of body fat stores
remains unclear [12]. Obesity induces a number of
metabolic disturbances known as the metabolic syn-
drome, and is associated with an excess risk of insulin
resistance, diabetes, and cardiovascular disease [13-15].
Obesity and related metabolic abnormalities are con-
sistent risk factors for CRC [16]. In most studies, obesity
(measured as BMI, waist circumference or waist-to-hip
ratio) is associated with a relative risk of 1.5 to 2.0 com-
pared with a low or normal BMI [17-20]. Similarly, asso-
ciations for circumference measures have been noted for
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most colon cancers [19,21,22]. Overall, the data strongly
support that some metabolic characteristics associated
with central or abdominal adiposity increases risk of
CRC.
Accumulating evidence also indicate a role of ghrelin
in cell proliferation, inhibition of apoptosis and cancer
development [23-26].
Polymorphisms in the coding region of the ghrelin
gene were suggested to be involved in the aetiology of
obesity and to modulate glucose-induced insulin secre-
tion in different ethnic study groups [27]. Hence, varia-
tions in the ghrelin gene influencing the expression and/
or function of the ghrelin protein might alter energy
balance, contribute to obesity and, indirectly, to CRC
risk. We postulate that Single Nucleotide Polymorph-
isms (SNPs) in the genes coding for ghrelin and its
receptor maybe associated with an altered risk of CRC.
In this report we investigated the genetic variability of
the GHRL and GHSR genes. Using a tagging approach
and selecting 7 SNPs in GHRL gene and 4 SNPs in the
GHSR gene we covered all the known genetic variation
of the two genes. We tested the impact of GHRL and
GHSR SNPs on CRC risk in a case-control study based
on subjects from the Czech Republic. In a second step
we replicated the best associations in an unrelated Ger-
man population. To our knowledge this is the first
report on polymorphisms of GHRL, GHSR and CRC
risk.
Methods
Study populations
In this study we have used two distinct populations: one
from Czech Republic and the other from Germany. All
SNPs were typed in the Czech population while only
two SNPs showing an altered risk of CRC in the first
population were typed in the German cases and
controls.
Czech population
The population has been extensively described elsewhere
[28,29]. Briefly: cases were CRC patients visiting nine
oncological departments (two in Prague, one each in
Benesov, Brno, Liberec, Ples, Pribram, Usti nad Labem,
and Zlin) distributed in all geographic regions of Czech
Republic and being representative of the population of
the entire country. This study includes 680 patients who
could be interviewed and provided biological samples of
sufficient quality for genetic analysis. All cases had his-
tological confirmation of their tumor diagnosis.
Controls were selected among patients admitted to five
large gastroenterological departments (Prague, Brno,
Jihlava, Liberec, and Pribram) all over the Czech Republic,
during the same period of the recruitment of cases.
Selected controls were all of Czech Caucasian origin. Only
subjects whose colonoscopic results were negative for
malignancy, colorectal adenomas or IBD were chosen as
controls. Among 739 invited controls, a total of 593
(80.2%) were analyzed in this study (lost controls were
similar to those included with respect to sex distribution).
Cases included in this study had a mean age of
61 years (range 27-90), while controls had a mean age
of 56 years (range 28-91). Study subjects provided infor-
mation on their lifestyle habits (smoking, drinking, diet
etc.), and family/personal history of cancer, with the use
of structured questionnaires.
The genetic analyses did not interfere with diagnostic
or therapeutic procedures for the subjects. All partici-
p a n t ss i g n e da ni n f o r m e dw r i t t e nc o n s e n ta n dt h e
design of the study was approved by the Ethical
Committee of the Institute of Experimental Medicine,
Prague, Czech Republic.
German population
CRC cases comprised 569 German Caucasian index
patients (age range 9-88 years, mean 43.6 years) recruited
by the six German university hospitals of Bochum (BO),
Bonn (BN), Dresden (DD), Düsseldorf (DÜ), Heidelberg
(HD) and Munich/Regensburg (MR). Cases were col-
lected as part of a large study on susceptibility to heredi-
tary nonpolyposis CRC (HNPCC). Inclusion criteria for
the cases were (i) a family history of CRC or (ii) CRC
diagnosed under the age of 50. Analysis for microsatellite
instability was applied as a pre-screening test prior to
mutation analysis in the MSH2 and MLH1 genes. All
cases were tested to be microsatellite stable.
The control series consisted of 726 healthy, unrelated,
sex-and age matched blood donors (26-68 years, mean
45.9 years) which were recruited between 2004 and
2006 by the Institute of Transfusion Medicine and
Immunology, Faculty of Mannheim, Germany. The
matching intervals for age were ‘younger than 30 years’,
five-year groups (30-34, 35-39, ..., 60-64) and ‘older than
65 years’. Blood sampling was performed during regular
blood donation according to German guidelines.
Selected controls were all of German Caucasian origin.
The study was approved by the competent local Ethics
Committees, and written informed consent was obtained
from all individuals.
Selection of tagging SNPs
We aimed at surveying the entire set of common
genetic variants in the GHRL and GHSR genes. For this
purpose, we used the Tagger algorithm [30] that was
developed to select maximally informative sets of
tagSNPs in candidate-gene association study. All poly-
morphisms in the region of the two genes of interest
with minor allele frequency (MAF) ≥5% in Caucasians
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http://www.hapmap.org), were included. Tagging SNPs
were selected with the use of the Tagger program within
Haploview http://www.broad.mit.edu/mpg/haploview/;
http://www.broad.mit.edu/mpg/tagger/[31,32], using
pairwise tagging with a minimum r
2 of 0.8.
This resulted in a selection of 11 tagging SNPs, 7 for the
GHRL gene (with a mean r
2 of the selected SNPs with the
SNPs they tag of 0.967), and 4 for the GHSR gene (with an
r
2 of 0.989). Our selection thus captures to a very high
degree the known common variability in this gene.
DNA extraction and genotyping
DNA was extracted from blood samples with standard
proteinase K digestion followed by phenol/chloroform
extraction and ethanol precipitation. The order of DNAs
from cases and controls was randomized on PCR plates
in order to ensure that an equal number of cases and
controls could be analyzed simultaneously. All the geno-
typing was carried out using the Taqman assay, accord-
ing to manufacturer’s protocol. The pre-designed
Taqman assays were purchased from Applied Biosys-
tems (Foster City, CA).
All samples that did not give a reliable result in the
first round of genotyping were resubmitted to up to two
additional rounds of genotyping. Data points that were
still not filled after this procedure were left blank.
Repeated quality control genotypes (8% of the total)
showed an average concordance of 99.5%.
Statistical Analysis
The frequency distribution of genotypes was examined
for the cases and the controls. Hardy-Weinberg equili-
brium was tested in the cases and in the controls sepa-
rately by chi square test. We used logistic regression for
multivariate analyses to assess the main effects of the
genetic polymorphism on CRC risk using a codominant
inheritance model. The most common allele in the con-
trols was assigned as the reference category. All analyses
were adjusted for age and sex.
Additionally, we performed a logistic regression strati-
fying for the cancer site (colon versus rectum) and
smoking (smokers versus non smokers and heavy smo-
kers versus light smokers) or alcohol drinking (drinkers
vs. non-drinkers) habits.
For SNPs rs27647 and rs35683 the analysis were per-
formed in the two populations. Odds ratios were calcu-
lated for the two populations separately and jointly.
All the analyses were performed with STATA software
(StataCorp, College Station, TX).
Results
We performed a case-control study using two different
sets of SNPs in two distinct populations of German and
Czech origins. The first SNP set was made of 11 tagging
SNPs which we tested in 680 cases and 593 controls
from the Czech Republic. The second SNP set consisted
of the two best hits, namely SNPs rs27647 and rs35683,
which we replicated in additional 569 cases and 726
controls from Germany. The genotype frequencies
among the controls were in Hardy-Weinberg equili-
brium for all the SNPs and in both populations.
Results for the Czech population
The distribution of the genotypes and their odds ratios
(ORs) for association with CRC risk are shown in Table 1.
We found that, in this sample set, carriers of the T
allele of SNP rs27647 had a decreased risk of CRC, with
an OR of 0.70 (95% confidence interval (95% CI) 0.55-
0.91; Pvalue = 0.013), for C/T heterozygous individuals
and an OR of 0.57 (95% CI 0.40-0.80; Pvalue =0 . 0 0 2 )f o r
T/T homozygous individuals (Ptrend = 0.001).
Moreover we found that carriers of the C allele of
SNP rs35683 had a decreased risk of CRC, with an OR
of0.71 (95% CI 0.51-0.98; Pvalue = 0.04) for C/C homozy-
gous individuals. The OR of 0.80 for the heterozygous
individuals was not statistically significant (95% CI 0.60-
1.05; Pvalue = 0.42) (Ptrend = 0.02).
We did not find any statistically significant association
between the other SNPs and CRC risk.
Results for the German population
The distribution of the genotypes and their odds ratios
(ORs) for association with CRC risk are shown in Table 2.
The associations found in the Czechs were not con-
firmed in the German population. However, the effect of
SNP rs27647 was statistically significant in a joint analysis
of data from the two populations. The carriers of the T
allele in the joint group exerted a protective effect, with an
OR of 0.82 (95% CI 0.69-0.98; Pvalue = 0.02), for C/T indi-
viduals and an OR of 0.73 (95% CI 0.58-0.93; Pvalue =0 . 0 1 )
for T/T homozygous individuals (Ptrend = 0.0043).
Applying the Bonferroni correction for multiple test-
ing the Ptrend of rs27647 in the joint population
remained borderline significant (Ptrend =0 . 0 0 4 3×1 1=
0.047), although neither the ORs for heterozygotes nor
for the homozygotes remained statistically significant
after correction. A test for heterogeneity indicated that
the results for the two populations were statistically dif-
ferent (Pheterogeneity = 0.014).
Stratified analysis and interactions
Analyses stratified by cancer site (colon vs. rectum),
alcohol and smoking habits did not show any significant
interaction with polymorphisms (data not shown).
We performed analysis stratified by age using the
median age as a cut off. In the German population we
found no difference in the genotype distribution in the
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Czech population we found that only in the older group
(age >66) the homozygous carriers of the variant alleles
of two SNPs showed a statistically significant association
with cancer risk: OR of 0.39 (95% CI 0.21-0.73 Pvalue =
0.003) for SNP rs27647 and OR of 0.46 (95% CI 0.28-
0.78 Pvalue = 0.004) for SNP rs35683.
Finally we performed an analysis combining the two
polymorphisms in order to assess the impact of cancer
risk of a multi-locus risk score, but the results did not
explain more of the genetic susceptibility to the disease
than the two SNPs alone (data not shown).
Discussion
Recent evidence indicates that obesity and related meta-
bolic abnormalities are associated with increased inci-
dence and mortality for CRC. Since it has been shown
that circulating levels of ghrelin are related to body size
we postulated that polymorphisms that could alter pro-
tein expression and/or function may also alter CRC risk.
In this study we investigated the genetic variability of
the GHRL and GHRS genes in relation to CRC risk
using a tagging approach and selecting 11 SNPs. Using
this method we covered all the known genetic variation
of the genes, an effort lacking from all previous studies.
On the first phase of the project we typed all the 11
tagging SNPs in CRC cases and controls from the Czech
Republic and we found that two SNPs (rs27647,
rs35683) were associated with a decreased risk of CRC.
SNP rs27647 is situated in the promoter region of the
gene and has been found associated with insulin level
and obesity [33], while SNP rs35683 is situated in the
first intron of the gene and has been found associated
w i t hB M Ii naC a u c a s i a np o p u l a t i o n [ 3 4 ] .S i n c eB M I ,
obesity and insulin level are well known risk factors for
CRC, the two SNPs may indirectly affect cancer risk.
We sought to replicate these findings in an independent
Table 1 Associations of GHRL and GHSR polymorphisms
with colorectal cancer risk in the Czech population
Cases
a Controls
a OR(95%)
b P value P trend
GHRL
rs26802
G/G 286 278 1
G/T 294 245 1.18(0.92-1.51) 0.18
T/T 93 74 1.19(0.82-1.70) 0.25 0.16
rs27647
C/C 279 198 1
C/T 289 280 0.70(0.55-0.91) 0.008
T/T 93 110 0.57(0.40-0.80) 0.002 0.001
rs35683
A/A 204 147 1
A/C 331 297 0.80(0.61-1.05) 0.11
C/C 137 143 0.71(0.51-0.98) 0.04 0.02
rs4684677
A/A 601 523 1
A/C 78 74 0.91(0.64-1.30) 0.49
C/C 4 3 1.63(0.35-7.68) 0.62 0.70
rs696217
G/G 590 523 1
G/T 84 71 1.09(0.77-1.55) 0.64
T/T 4 6 0.60(0.16-2.18) 0.43 0.89
rs2075356
C/C 559 498 1
C/T 101 78 1.20(0.86-1.68) 0.63
T/T 7 7 0.88(0.30-2.61) 0.36 0.28
rs35684
A/A 257 248 1
A/G 213 174 1.10(0.84-1.43) 0.46
G/G 47 34 1.24(0.77-2.00) 0.36 0.29
GHSR
rs2922126
T/T 255 20 1
A/T 269 274 0.81(0.62-1.05) 0.11
A/A 74 39 1.48(0.95-2.30) 0.82 0.31
rs2944694
A/A 564 477
A/G 98 101 0.78(0.57-1.07) 0.14
G/G 7 11 0.46(0.16-1.28 0.14 0.08
rs495225
A/A 333 293 1
A/G 232 220 0.88 (0.68-1.13) 0.33
G/G 58 42 1.17(0.75-1.83) 0.47 0.77
rs572169
C/C 329 305 1
C/T 263 235 1.03(0.80-1.31) 0.80
T/T 57 48 1.14(0.74-1.74) 0.55 0.62
a Numbers may not add up to 100% of subjects due to genotyping failure. All
samples that did not give a reliable result in the first round of genotyping
were resubmitted to up to two additional rounds of genotyping. Data points
that were still not filled after this procedure were left blank.
b OR: odds ratio; CI: confidence interval. Adjusted for age and gender. Results
in bold are statistically significant (p < 0.05)
Table 2 Associations of GHRL polymorphisms with
colorectal cancer risk in the German cases and controls
Cases
a Controls
a OR(95%)
b P value P trend
rs27647 GHRL
C/C 213 259 1
C/T 278 360 0.93(0.73-1.19) 0.60
T/T 78 107 0.83(0.62-1.24) 0.49 0.54
rs35683 GHRL
A/A 172 220 1
A/C 277 356 0.99(0.77-1.28) 0.97
C/C 120 150 0.99(0.72-1.35) 0.95 0.99
a Numbers may not add up to 100% of subjects due to genotyping failure. All
samples that did not give a reliable result in the first round of genotyping
were resubmitted to up to two additional rounds of genotyping. Data points
that were still not filled after this procedure were left blank.
b OR: odds ratio; CI: confidence interval. Adjusted for age and gender. Results
in bold are statistically significant (p < 0.05)
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sample size. In this second population the findings were
not replicated.
There are two possible explanations for these findings:
either the associations observed from the Czech popula-
tion are false positives, or the differences in the associa-
tion results are due to differences between the two
selected populations. We can confidently exclude a
major role of ethnic differences. According to Globocan
[35-37], the Czech and the German populations have a
comparable CRC incidence. Moreover in a recent study
Nelis and colleagues investigated the underlying popula-
tion stratification in Europe showing that there were
very little, if any, differences in the genetic make-up of
Germans and Czechs [38]. Another explanation for the
inconsistent findings may be due to different environ-
mental factors in the two countries. However dietary
habits and food intake are not dramatically different in
the two countries http://faostat.fao.org/site/609/Desk-
topDefault.aspx?PageID = 609. It has to be noted that
the German subjects were on average young and had a
family history of CRC, whereas the Czech cases were
unselected.. It may be speculated that genetic predispo-
sition to familial and sporadic cases is due to groups of
genetic variants that do not overlap entirely. According
to this hypothesis, rs27647 could be more relevant for
sporadic cases but not for familial ones. In addition if
ghrelin acts indirectly through the effects of increased
BMI, Germans subjects may not have been old enough
to have had sufficient exposure to increased BMI to
show the increased incidence of cancer. In fact, when
we stratified the analysis for age groups, only in the
older patients the observed association remained signifi-
cant. Finally, it has not to be overlooked that ORs for
rs27647 were similar in the two groups, but the effect
does not reach statistical significance in the Germans,.
This may indicate that the association could be true,
and a larger, independent study is needed to confirm or
disproof this finding.
Conclusion
In conclusion, we are not able to completely exclude a
possible effect of the rs27647 SNP in CRC risk, while
we can confidently exclude a major role for the other
common SNPs in GHRL and GHSR as CRC risk factors.
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